Merck discontinues Phase 3 KeyVibe-010 trial
The trial was discontinued after results showed that the coformulation of vibostolimab and pembrolizumab for treatment of resected…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Melanoma
Pfizer’s Braftovi to command 42 per cent share of BRAF inhibitors melanoma market by 2028:…
GlobalData’s patient-based forecast reveals that the BRAF inhibitor market for melanoma will reach a key milestone by 2028, with…
Merck and Moderna initiate phase 3 study evaluating V940
V940-001 is the first phase 3 study of a planned comprehensive clinical development program being initiated following the positive…
Roche gets US FDA approval for Tecentriq combo to treat advanced melanoma
The approval is based on results from the Phase III IMspire150 study, in which the addition of Tecentriq to Cotellic and Zelboraf…
Scientists double understanding of genetic risk of melanoma
Melanoma is a sometimes-deadly skin cancer, with an estimated 350,000 cases worldwide in 2015, resulting in nearly 60,000 deaths…
Researchers develop effective nano-vaccine for melanoma
The focus of the research, published in the journal Nature Nanotechnology, is on a nanoparticle that serves as the basis for the…
Melanoma treatment market value to more than quadruple to $5.64 bn by 2023: GlobalData
The global treatment market for melanoma will expand more than fourfold in value from $1.34 billion in 2013 to reach an estimated…